Clinical Trials
88 trialsABBY
Abramson Cancer Center at Penn Medicine
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
Northwestern University
PHL Treatment in Pancreatic Cancer
Fox Chase Cancer Center
Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma
M.D. Anderson Cancer Center
THREAD
University of Utah
COAST
Medical University of South Carolina
LIMIT
Abramson Cancer Center at Penn Medicine
PALAVY
Abramson Cancer Center at Penn Medicine
Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
HCQ in Resectable Localized Prostate Cancer
Dartmouth-Hitchcock Medical Center
Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer
Emory University
Autophagy Maintenance (AUTOMAIN)
Medical University of South Carolina
Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer
University Health Network, Toronto
Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations
Massachusetts General Hospital
Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
The University of Texas Health Science Center at San Antonio
Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer
HonorHealth Research Institute
A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer
Abramson Cancer Center at Penn Medicine
CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer
Abramson Cancer Center at Penn Medicine
Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19
Memorial Sloan Kettering Cancer Center
RIOM
West China Hospital
Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer
Asan Medical Center
Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer
University of Kentucky
Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
Abramson Cancer Center at Penn Medicine
Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients
Affiliated Hospital of Nantong University
Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer
M.D. Anderson Cancer Center
LY3214996 +/- HCQ in Pancreatic Cancer
Dana-Farber Cancer Institute
MEKiAUTO
Columbia University
OHSS
Aljazeera Hospital
UTAH
University of Utah
TACE-Ax-HCQ
Abramson Cancer Center at Penn Medicine
HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Evaluation of Hydroxychloroquine to Prevent CIPN
University of Arizona
Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer
The University of Texas Health Science Center at San Antonio
HITMAN-PC
St Vincent's Hospital, Sydney
To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer
Abramson Cancer Center at Penn Medicine
Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer
Rutgers, The State University of New Jersey
Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer
Rutgers, The State University of New Jersey
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Northwestern University
Hydroxychloroquine + Vorinostat in Advanced Solid Tumors
The University of Texas Health Science Center at San Antonio
Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
Medical College of Wisconsin
Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
Rutgers, The State University of New Jersey
Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery
Rutgers, The State University of New Jersey
Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer
Rutgers, The State University of New Jersey
MYELOMA-HCQ
Norwegian University of Science and Technology
Biological Effects of Agent on PAR-4 Levels With Resected Solid Tumors
University of Kentucky
A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy
Memorial Sloan Kettering Cancer Center
HCQMa
University Hospital, Toulouse
Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Rutgers, The State University of New Jersey
HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors
University of Kentucky